COMPARATIVE STUDY
JOURNAL ARTICLE
MULTICENTER STUDY

Comparison of vascular closure devices for access site closure after transfemoral aortic valve implantation

Israel M Barbash, Marco Barbanti, John Webb, Javier Molina-Martin De Nicolas, Yigal Abramowitz, Azeem Latib, Caroline Nguyen, Florian Deuschl, Amit Segev, Konstantinos Sideris, Sergio Buccheri, Matheus Simonato, Francesco Della Rosa, Corrado Tamburino, Hasan Jilaihawi, Tadashi Miyazaki, Dominique Himbert, Niklas Schofer, Victor Guetta, Sabine Bleiziffer, Didier Tchetche, Sebastiano Immè, Raj R Makkar, Alec Vahanian, Hendrik Treede, Rüdiger Lange, Antonio Colombo, Danny Dvir
European Heart Journal 2015 December 14, 36 (47): 3370-9
26314688

BACKGROUND: The majority of transcatheter aortic valve implantation (TAVI) procedures are currently performed by percutaneous transfemoral approach. The potential contribution of the type of vascular closure device to the incidence of vascular complications is not clear.

AIM: To compare the efficacy of a Prostar XL- vs. Perclose ProGlide-based vascular closure strategy.

METHODS: The ClOsure device iN TRansfemoral aOrtic vaLve implantation (CONTROL) multi-center study included 3138 consecutive percutaneous transfemoral TAVI patients, categorized according to vascular closure strategy: Prostar XL- (Prostar group) vs. Perclose ProGlide-based vascular closure strategy (ProGlide group). Propensity-score matching was used to assemble a cohort of patients with similar baseline characteristics.

RESULTS: Propensity matching identified 944 well-matched patients (472 patient pairs). Composite primary end point of major vascular complications or in-hospital mortality occurred more frequently in Prostar group when compared with ProGlide group (9.5 vs. 5.1%, P = 0.016), and was driven by higher rates of major vascular complication (7.4 vs. 1.9%, P < 0.001) in the Prostar group. However, in-hospital mortality was similar between groups (4.9 vs. 3.5%, P = 0.2). Femoral artery stenosis occurred less frequently in the Prostar group (3.4 vs. 0.5%, P = 0.004), but overall, Prostar use was associated with higher rates of major bleeding (16.7 vs. 3.2%, P < 0.001), acute kidney injury (17.6 vs. 4.4%, P < 0.001) and with longer hospital stay (median 6 vs. 5 days, P = 0.007).

CONCLUSIONS: Prostar XL-based vascular closure in transfemoral TAVI procedures is associated with higher major vascular complication rates when compared with ProGlide; however, in-hospital mortality is similar with both devices.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
26314688
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"